These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2776392)

  • 1. Multiple pathways of propranolol's metabolism are inhibited by debrisoquin.
    Anthony L; Koshakji R; Wood AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):297-300. PubMed ID: 2776392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
    Shaheen O; Biollaz J; Koshakji RP; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.
    McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW
    Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of propranolol metabolism by rifampicin.
    Herman RJ; Nakamura K; Wilkinson GR; Wood AJ
    Br J Clin Pharmacol; 1983 Nov; 16(5):565-9. PubMed ID: 6639842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS; Jackson PR; Freestone S; Ramsay LE; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract]   [Full Text] [Related]  

  • 8. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.
    Zhou HH; Anthony LB; Roden DM; Wood AJ
    Clin Pharmacol Ther; 1990 Jun; 47(6):686-93. PubMed ID: 2357863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade.
    Raghuram TC; Koshakji RP; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1984 Jul; 36(1):51-6. PubMed ID: 6734049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites.
    Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
    J Pharmacol Exp Ther; 1987 Jun; 241(3):928-33. PubMed ID: 3598909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil.
    Shaheen O; Patel J; Avant GR; Hamilton M; Wood AJ
    Clin Pharmacol Ther; 1986 Dec; 40(6):650-5. PubMed ID: 3780126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration.
    Riddle MA; Leckman JF; Cohen DJ; Anderson M; Ort SI; Caruso KA; Shaywitz BA
    J Neural Transm; 1986; 67(1-2):31-43. PubMed ID: 3465864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method.
    Riddle MA; Jatlow PI; Anderson GM; Cho SC; Hardin MT; Cohen DJ; Leckman JF
    Neuropsychopharmacology; 1989 Jun; 2(2):123-9. PubMed ID: 2742727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J; LLerena A; Cobaleda J
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between oral propranolol and hydralazine.
    McLean AJ; Skews H; Bobik A; Dudley FJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):726-32. PubMed ID: 7379440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population study of poor debrisoquine-type metabolizers of propranolol among Japanese.
    Hayashi M; Takase M
    Jpn J Ophthalmol; 1985; 29(3):272-81. PubMed ID: 4079124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypotensive response to debrisoquine and hydroxylation phenotype.
    Idle JR; Mahgoub A; Lancaster R; Smith RL
    Life Sci; 1978 Mar; 22(11):979-83. PubMed ID: 642709
    [No Abstract]   [Full Text] [Related]  

  • 20. Proceedings: Parasympathetic blockade in patients treated with debrisoquine and with propranolol.
    Aminu J
    West Afr J Pharmacol Drug Res; 1974 Dec; 2(1):53P-54P. PubMed ID: 4470635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.